180 Life Sciences Corporate Media Kit

17 Additional Indications • Over 300,000 hip fractures each year in the U.S. alone (1) • Strong clinical evidence for anti-TNF as preventative therapy • Patent claims granted, patent is licensed from Kennedy Trust, UK • Phase 2 multi-centre trial of pre-operative anti-TNF in hip fracture surgery planned to initiate by Q4 2021, single dose administered just prior to surgery, to be complete in 4 years Post Operative Delirium/Cognitive Deficit (POCD) Frozen Shoulder • Affects 9% of the of the population aged 25-64yr, more common in diabetics (2) • Only treatment for early stage is local steroid injection for short term relief • Phase 2 clinical trials planned for local injection of anti- TNF, initiates Q3 2021 in the UK • Trial protocol completed and £250,000 NIHR grant received (1) https://www.cdc.gov/homeandrecreationalsafety/falls/adulthipfx.html (2) Walker-Bone K et al (2004) Arthritis Rheum 51(4):642-651 (3) Rinella ME & Sanyal AJ (2016) Nat Rev Gastroenterol Hepatol 13(4):196-205 (4) Ibid. Fibrosis of the Liver (NASH) • Most commonly caused by non-alcoholic fatty liver disease (NAFLD), which affects ~30% of the US population (3) • ~2% of patients with non-alcoholic fatty liver disease and 15-20% with non-alcoholic steatohepatitis (NASH) progress to cirrhosis (4) • No approved therapeutic for NASH • Lab program in collaboration with Celgene-BMS for target discovery using human liver samples 180 Life Sciences Corp. www.180lifesciences.com Q4 2020